MVEN yields 17547.44% · ABBV yields 3.06%● Live data
📍 MVEN pulled ahead of the other in Year 1
Combined, MVEN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MVEN + ABBV for your $10,000?
TheMaven, Inc. operates a technology platform in the United States. The company operates the Maven platform, an online publishing platform consisting of publishing tools, video platforms, commenting features, social distribution channels, newsletter technology, machine learning content recommendations, notifications, and other technology that delivers various features to drive a digital media business in cloud-based suite of services that provides owned and operated media businesses, Publisher Partners, and individual creators the ability to produce and manage editorially focused content through tools and services. It develops advertising technology, techniques, and relationships that allow its publisher partners and expert contributors to monetize online editorially focused content through various display and video advertisements tools and services for driving a subscription or membership-based business and other monetization services. It also operates a coalition of professionally managed online media channels on third party cloud platforms and data center hosting facilities. The company's Publishing Partners publish content and oversee an online community for their sites and leverages its technology platform to engage the collective audiences within a single network. TheMaven, Inc. was incorporated in 1990 and is based in New York, New York.
Full MVEN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.